Company Filing History:
Years Active: 2022
Title: Hwa Sil Kim: Innovator in LRRK2 Inhibitors
Introduction
Hwa Sil Kim is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target degenerative brain diseases. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Hwa Sil Kim holds a patent for "Substituted pyrazoles as LRRK2 inhibitors." This patent describes a pyrrolo(pyrazolo)pyrimidine compound of Formula 1, along with its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, and isomers. The compound demonstrates excellent LRRK2 inhibitory activity, making it a promising candidate for treating or preventing degenerative brain diseases. The patent also outlines methods for manufacturing the compound and its applications in pharmaceutical compositions.
Career Highlights
Hwa Sil Kim is currently associated with Oscotec Inc., a company known for its focus on innovative drug development. His work at Oscotec has allowed him to collaborate with other talented professionals in the field, further enhancing the impact of his research.
Collaborations
Some of Hwa Sil Kim's notable coworkers include Jung-Ho Kim and Jang-Sik Choi. Their collaborative efforts contribute to the advancement of research and development in the pharmaceutical industry.
Conclusion
Hwa Sil Kim's contributions to the field of pharmaceuticals, particularly through his patent on LRRK2 inhibitors, highlight his role as an innovator in medical science. His work has the potential to significantly impact the treatment of degenerative brain diseases, showcasing the importance of innovation in healthcare.